ankylosing%20spondylitis
ANKYLOSING SPONDYLITIS
Spondyloarthritis refers to a group of inflammatory diseases characterized by spinal & joint oligoarthritis, enthesitis, and sometimes mucocutaneous, ocular and/or cardiac manifestations.
Ankylosing spondylitis is a prototype of spondyloarthritis, particularly of the axial form.
Diagnosis of ankylosing spondylitis is definite if any of the radiological criterion (grade≥2 bilateral sacroiliitis or grade ≥3 unilateral sacroiliitis) is associated with at least one of the clinical criterion (low back pain & stiffness for >3 months that improves with exercise but not relieved by rest, limitation of motion of the lumbar spine in the sagittal and frontal planes, limitation of chest expansion relative to normal values correlated for age and gender.

Surgical Intervention

  • Collaboration with orthopedic surgeon to consider the following:
    • Total hip arthroplasty in ankylosing spondylitis (AS) patients with refractory pain/disability, structural damage as seen in radiographs
    • Spinal corrective osteotomy in ankylosing spondylitis (AS) patients with severe disabling deformity (eg severe kyphosis)
  • Recommend consultation with spinal surgeon in ankylosing spondylitis (AS) patients with acute vertebral fracture
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
23 Nov 2017
In patients with rheumatoid arthritis (RA) who are also positive for anticitrullinated protein antibodies (ACPA), tocilizumab (TCZ) treatment for 2 years increases femoral neck bone mineral density (BMD) and decreases concentrations of bone resorption markers, a recent study has found.
12 Nov 2017
Tocilizumab may improve skin score and forced vital capacity stabilization in patients with systemic sclerosis, while potentially increasing the risk of serious infections, according to the open-label data of the faSScinate* trial.
Audrey Abella, 21 Nov 2017
The infliximab (IFX) biosimilar SB2, whether administered long-term or switched from IFX, had comparable efficacy and safety as IFX for rheumatoid arthritis (RA), a study has found.
30 Nov 2017
There are significant associations between comorbidities and hand osteoarthritis (OA) disease burden, a recent study has found.